secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001641172-25-016387
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%
--------------------------------------------------------------------------------

- Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
- 92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.
- Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.
- Glucotrack expects to initiate long-term early feasibility study in Q3 2025.
- OneTwo Analytics applied AI/ML analytics to validate performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/0001641172-25-016387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer